This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Alexander JI , Vendramini-Costa DB , Francescone R , Luong T , Franco-Barraza J , Shah N , Gardiner JC , Nicolas E , Raghavan KS , Cukierman E
Palladin isoforms 3 and 4 regulate cancer-associated fibroblast pro-tumor functions in pancreatic ductal adenocarcinoma
Sci Rep. 2021 Feb 15;11(1) :3802
PMID: 33589694 PMCID: PMC7884442
AbstractPancreatic Ductal Adenocarcinoma (PDAC) has a five-year survival under 10%. Treatment is compromised due to a fibrotic-like stromal remodeling process, known as desmoplasia, which limits therapeutic perfusion, supports tumor progression, and establishes an immunosuppressive microenvironment. These processes are driven by cancer-associated fibroblasts (CAFs), functionally activated through transforming growth factor beta1 (TGFβ1). CAFs produce a topographically aligned extracellular matrix (ECM) that correlates with reduced overall survival. Paradoxically, ablation of CAF populations results in a more aggressive disease, suggesting CAFs can also restrain PDAC progression. Thus, unraveling the mechanism(s) underlying CAF functions could lead to therapies that reinstate the tumor-suppressive features of the pancreatic stroma. CAF activation involves the f-actin organizing protein palladin. CAFs express two palladin isoforms (iso3 and iso4) which are up-regulated in response to TGFβ1. However, the roles of iso3 and iso4 in CAF functions remain elusive. Using a CAF-derived ECM model, we uncovered that iso3/iso4 are required to sustain TGFβ1-dependent CAF activation, secrete immunosuppressive cytokines, and produce a pro-tumoral ECM. Findings demonstrate a novel role for CAF palladin and suggest that iso3/iso4 regulate both redundant and specific tumor-supportive desmoplastic functions. This study highlights the therapeutic potential of targeting CAFs to restore fibroblastic anti-tumor activity in the pancreatic microenvironment.
Notes2045-2322 Alexander, J I Vendramini-Costa, D B Francescone, R Luong, T Franco-Barraza, J Shah, N Gardiner, J C Nicolas, E Raghavan, K S Cukierman, E Orcid: 0000-0002-1452-9576 R21 CA231252/CA/NCI NIH HHS/United States S10 OD023666/OD/NIH HHS/United States 20-0081/AICR_/Worldwide Cancer Research/United Kingdom R01 CA232256/CA/NCI NIH HHS/United States T32 CA009035/CA/NCI NIH HHS/United States CA06927/Foundation for the National Institutes of Health/ T32CA009035/NIH/NCI T32 Training Grant/ 132561-PF-18-218-01-CSMA/American Cancer Society/ P30 CA006927/CA/NCI NIH HHS/United States Journal Article Sci Rep. 2021 Feb 15;11(1):3802. doi: 10.1038/s41598-021-82937-3.